(Q34786118)

4 August 2017

1 reference

title

How pharmacokinetic and pharmacodynamic drug monitoring can improve outcome in solid organ transplant recipients (English)

1 reference

4 August 2017

1 reference

1 reference

3

Teun van Gelder

1 reference

4 August 2017

Jochen Klupp

1

1 reference

4 August 2017

David W Holt

series ordinal

2

1 reference

4 August 2017

publication date

1 May 2002

1 reference

4 August 2017

published in

Transplant Immunology

1 reference

4 August 2017

volume

9

1 reference

4 August 2017

issue

2-4

1 reference

4 August 2017

page(s)

211-214

1 reference

Immunosuppressant drugs--the role of therapeutic drug monitoring

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Immunological and pharmacological monitoring in the clinical use of cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Cyclosporin blood levels do correlate with clinical complications

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

The temporal profile of calcineurin inhibition by cyclosporine in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Reci

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Therapeutic monitoring of mycophenolic acid. A consensus panel report

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Human type I and II IMP dehydrogenases as drug targets

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Mechanism of action of mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Pharmacodynamic monitoring of mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Pharmacodynamics of mycophenolic acid in heart allograft recipients: correlation of lymphocyte proliferation and activation with pharmacokinetics and graft histology

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Pharmacodynamics of immunosuppressive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Monitoring new immunosuppressive agents. Are the methods adequate?

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

Quality assessment issues of new immunosuppressive drugs and experimental experience

1 reference

https://api.crossref.org/works/10.1016%2FS0966-3274%2802%2900024-2

7 January 2021

10.1016/S0966-3274(02)00024-2

Identifiers

DOI

1 reference

4 August 2017

1 reference